Anixa Biosciences (ANIX) Corporate presentation summary

Business overview and financials

• Clinical-stage company focused on developing first-in-class cancer treatments and prevention products.

• Maintains a strong balance sheet with $14M in cash and short-term investments as of January 31, 2026.

• Operates a capital-efficient model with no debt, no warrants, and no preferred stock; annual cash burn of $5-7M.

• Consistent insider buying and a clean capital table support investor confidence.

• Programs are developed with partners, leveraging their infrastructure to keep overhead low.

Clinical pipeline and partnerships

• Pipeline includes CAR-T therapy for ovarian cancer, breast cancer vaccine, and pre-clinical vaccines for ovarian, lung, colon, and prostate cancers.

• Key partnerships with Moffitt Cancer Center, The Wistar Institute, Cleveland Clinic, and NIH.

• CAR-T program (Lira-cel) is in Phase 1 for ovarian cancer; breast cancer vaccine completed Phase 1 and is entering Phase 2.

• Pre-clinical studies underway for additional cancer vaccines using advanced AI and bioinformatics.

CAR-T program highlights

• Lira-cel targets FSHR, a receptor found primarily on ovarian cells and tumor vasculature, enabling a dual mechanism: direct tumor cell killing and anti-angiogenesis.

• Intraperitoneal delivery of CAR-T cells enhances tumor targeting and minimizes systemic side effects.

• Dose-escalation Phase 1 trial in recurrent/chemoresistant ovarian cancer is ongoing, with multiple cohorts and increasing cell doses.

• Early patient data show extended survival in some treated patients.